JP2013505713A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505713A5 JP2013505713A5 JP2012530319A JP2012530319A JP2013505713A5 JP 2013505713 A5 JP2013505713 A5 JP 2013505713A5 JP 2012530319 A JP2012530319 A JP 2012530319A JP 2012530319 A JP2012530319 A JP 2012530319A JP 2013505713 A5 JP2013505713 A5 JP 2013505713A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- chimeric polypeptide
- membrane
- polypeptide
- interest
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 116
- 102000004196 processed proteins & peptides Human genes 0.000 claims 94
- 229920001184 polypeptide Polymers 0.000 claims 88
- 239000012528 membrane Substances 0.000 claims 34
- 210000001808 exosome Anatomy 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 15
- 108091033319 polynucleotide Proteins 0.000 claims 10
- 102000040430 polynucleotide Human genes 0.000 claims 10
- 239000002157 polynucleotide Substances 0.000 claims 10
- 239000007857 degradation product Substances 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 230000008685 targeting Effects 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 210000000170 cell membrane Anatomy 0.000 claims 6
- 235000018102 proteins Nutrition 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 241000894006 Bacteria Species 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 230000000890 antigenic effect Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 239000000232 Lipid Bilayer Substances 0.000 claims 4
- 230000001086 cytosolic effect Effects 0.000 claims 4
- 238000012217 deletion Methods 0.000 claims 4
- 230000037430 deletion Effects 0.000 claims 4
- 244000045947 parasite Species 0.000 claims 4
- 238000006467 substitution reaction Methods 0.000 claims 4
- 230000001225 therapeutic effect Effects 0.000 claims 4
- 241000714266 Bovine leukemia virus Species 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 108010052285 Membrane Proteins Proteins 0.000 claims 3
- 102000018697 Membrane Proteins Human genes 0.000 claims 3
- 208000030852 Parasitic disease Diseases 0.000 claims 3
- 108010007100 Pulmonary Surfactant-Associated Protein A Proteins 0.000 claims 3
- 102100027773 Pulmonary surfactant-associated protein A2 Human genes 0.000 claims 3
- 230000036755 cellular response Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000008348 humoral response Effects 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 3
- 238000001727 in vivo Methods 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 150000002632 lipids Chemical class 0.000 claims 3
- NRZWYNLTFLDQQX-UHFFFAOYSA-N p-tert-Amylphenol Chemical compound CCC(C)(C)C1=CC=C(O)C=C1 NRZWYNLTFLDQQX-UHFFFAOYSA-N 0.000 claims 3
- 230000001717 pathogenic effect Effects 0.000 claims 3
- 108091005703 transmembrane proteins Proteins 0.000 claims 3
- 102000035160 transmembrane proteins Human genes 0.000 claims 3
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000007792 addition Methods 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000004443 dendritic cell Anatomy 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims 2
- 125000002686 geranylgeranyl group Chemical group [H]C([*])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])/C([H])=C(C([H])([H])[H])/C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims 2
- 210000003630 histaminocyte Anatomy 0.000 claims 2
- 210000000987 immune system Anatomy 0.000 claims 2
- 210000001821 langerhans cell Anatomy 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000036281 parasite infection Effects 0.000 claims 2
- 244000052769 pathogen Species 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- -1 DNA Chemical class 0.000 claims 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 241000699670 Mus sp. Species 0.000 claims 1
- 102000011931 Nucleoproteins Human genes 0.000 claims 1
- 108010061100 Nucleoproteins Proteins 0.000 claims 1
- 235000021314 Palmitic acid Nutrition 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 235000003704 aspartic acid Nutrition 0.000 claims 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 claims 1
- 125000004030 farnesyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])C([H])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000010348 incorporation Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 229940105132 myristate Drugs 0.000 claims 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims 1
- 210000004897 n-terminal region Anatomy 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 210000004989 spleen cell Anatomy 0.000 claims 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 claims 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0904576A FR2950350B1 (fr) | 2009-09-24 | 2009-09-24 | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
| FR09/04576 | 2009-09-24 | ||
| PCT/FR2010/052006 WO2011036416A1 (fr) | 2009-09-24 | 2010-09-23 | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013505713A JP2013505713A (ja) | 2013-02-21 |
| JP2013505713A5 true JP2013505713A5 (https=) | 2013-04-25 |
| JP5932647B2 JP5932647B2 (ja) | 2016-06-08 |
Family
ID=42107419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530319A Active JP5932647B2 (ja) | 2009-09-24 | 2010-09-23 | エキソソームに結合した目的のポリペプチドの分泌を可能にする新規キメラポリヌクレオチド及びポリペプチド、並びにその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9611481B2 (https=) |
| EP (1) | EP2480672B8 (https=) |
| JP (1) | JP5932647B2 (https=) |
| CA (1) | CA2775151C (https=) |
| FR (1) | FR2950350B1 (https=) |
| WO (1) | WO2011036416A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014150150A1 (en) * | 2013-03-15 | 2014-09-25 | Novavax, Inc. | Enhanced expression of picornavirus proteins |
| US10538570B2 (en) * | 2013-09-30 | 2020-01-21 | Northwestern University | Targeted and modular exosome loading system |
| PL228341B1 (pl) * | 2014-04-21 | 2018-03-30 | Bio Ventures Inst Spolka Z Ograniczona Odpowiedzialnoscia | Sposób uzyskiwania białka poliepitopowego oraz wektor DNA do realizacji tego sposobu |
| WO2016138525A1 (en) | 2015-02-27 | 2016-09-01 | University Of Washington | Polypeptide assemblies and methods for the production thereof |
| US10702581B2 (en) | 2015-05-04 | 2020-07-07 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
| AU2017335084B2 (en) * | 2016-09-30 | 2023-06-29 | Ilias Biologics Inc. | Compositions containing protein loaded exosome and methods for preparing and delivering the same |
| SMT202200156T1 (it) | 2018-11-16 | 2022-05-12 | Codiak Biosciences Inc | Vescicole extracellulari ingegnerizzate e loro usi |
| IT201900000651A1 (it) | 2019-01-16 | 2019-04-16 | Pastore Lucio | Tecnologia di trasferimento genico |
| US20240108747A1 (en) | 2019-03-21 | 2024-04-04 | Lonza Sales Ag | Extracellular vesicle conjugates and uses thereof |
| SG11202111290WA (en) | 2019-04-17 | 2021-11-29 | Codiak Biosciences Inc | Compositions of exosomes and aav |
| WO2021045501A1 (ko) * | 2019-09-02 | 2021-03-11 | 경북대학교 산학협력단 | Il-2 표면 발현 세포외 소포체를 유효성분으로 포함하는 암 질환 예방 또는 치료용 조성물 |
| WO2021144363A1 (en) | 2020-01-14 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antigenic reactivity of a peptide mimicking the glycan loop of flaviviruses envelope protein |
| WO2021154888A1 (en) * | 2020-01-27 | 2021-08-05 | Mantra Bio. Inc. | Non-naturally occurring vesicles comprising a chimeric vesicle localization moiety, methods of making and uses thereof |
| JP2023512562A (ja) | 2020-02-05 | 2023-03-27 | ダイアデム バイオセラピューティクス インコーポレイテッド | 人工シナプス |
| WO2021184021A1 (en) | 2020-03-13 | 2021-09-16 | Codiak Biosciences, Inc. | Extracellular vesicle-aso constructs targeting pmp22 |
| EP4138907A4 (en) * | 2020-04-20 | 2024-08-21 | The General Hospital Corporation | IMMUNOGENIC COMPOSITION OF CORONAVIRUS WITH EPITOPES HAVING HIGH NETWORK SCORE |
| WO2021237100A1 (en) | 2020-05-21 | 2021-11-25 | Codiak Biosciences, Inc. | Methods of targeting extracellular vesicles to lung |
| CN116194462B (zh) * | 2020-08-11 | 2025-07-18 | 庆北大学校产学协力团 | 选择性结合癌细胞来源外泌体的肽及其用途 |
| EP3973985A1 (en) * | 2020-09-29 | 2022-03-30 | Ciloa | Extracellular vesicles harboring a spike protein, nucleic acids for producing the same, and method of immunizing a subject against sars-cov-2 using the same |
| CN113480666B (zh) * | 2021-08-13 | 2024-01-26 | 郑州伊美诺生物技术有限公司 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
| WO2023222890A1 (en) | 2022-05-20 | 2023-11-23 | Ciloa | Reversible loading of proteins in the lumen of extracellular vesicles |
| EP4612190A2 (en) * | 2022-11-02 | 2025-09-10 | Pioneer Biolabs, LLC | Systems and methods for single cell detection of protein secretion |
| EP4719600A1 (en) * | 2023-06-05 | 2026-04-08 | Ciloa | Chimeric polypeptides, extracellular vesicles comprising the same, and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL160142A0 (en) * | 2001-08-17 | 2004-06-20 | Anosys Inc | Methods and compounds for the targeting of protein to exosomes |
| EP1483372A2 (en) | 2002-03-14 | 2004-12-08 | Anosys, Inc. | Functionalization of t cell derived vesicles and use thereof for the preparation of immunogenic pharmaceutical compositions |
| JP4939926B2 (ja) * | 2003-02-14 | 2012-05-30 | アノシス・インコーポレーテッド | 抗体を生成し抗体レパートリーをスクリーニングするための方法とコンパウンド |
| FR2928926B1 (fr) | 2008-03-18 | 2015-08-21 | Centre Nat Rech Scient | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
-
2009
- 2009-09-24 FR FR0904576A patent/FR2950350B1/fr active Active
-
2010
- 2010-09-23 CA CA2775151A patent/CA2775151C/fr active Active
- 2010-09-23 JP JP2012530319A patent/JP5932647B2/ja active Active
- 2010-09-23 WO PCT/FR2010/052006 patent/WO2011036416A1/fr not_active Ceased
- 2010-09-23 EP EP10769025.7A patent/EP2480672B8/fr active Active
- 2010-09-23 US US13/497,779 patent/US9611481B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505713A5 (https=) | ||
| US20240066096A1 (en) | pHLIP® peptide mediated epitope tethering at cell surfaces | |
| RU2624041C2 (ru) | Конструкции гомодимерных белков | |
| CN100590131C (zh) | 用于将蛋白定向到胞外体的方法和化合物 | |
| JP2001515711A (ja) | Ｋａｙ−新規の免疫系タンパク質 | |
| CN113329762A (zh) | 用于合成肽免疫原作为免疫刺激剂的人工混杂t辅助细胞表位 | |
| JP7146926B2 (ja) | Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン | |
| US20100028353A1 (en) | Anti-amyloid immunogenic compositions, methods and uses | |
| JP2010532656A (ja) | 癌退縮抗原ｎｙ−ｅｓｏ−１およびｌａｇｅ−１を含む融合タンパク質 | |
| CN104136039A (zh) | 靶向交叉呈递的树突状细胞的疫苗体 | |
| Li et al. | Surface display of classical swine fever virus E2 glycoprotein on gram-positive enhancer matrix (GEM) particles via the SpyTag/SpyCatcher system | |
| CN117586358A (zh) | 一种具有免疫原性的呼吸道合胞病毒（rsv）多肽 | |
| KR102427429B1 (ko) | 자기조립형 합성 단백질 | |
| US8309096B2 (en) | Fusion protein | |
| WO2025241210A1 (zh) | RSV pre-F突变体及其生产方法和用途 | |
| JP4299777B2 (ja) | 免疫応答を誘導するための方法および組成物 | |
| KR20240163165A (ko) | 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법 | |
| JP7045024B2 (ja) | マラリアワクチン | |
| JP2024529044A (ja) | レプトスピラ病毒性調節タンパク質とその使用 | |
| US20210347866A1 (en) | Peptide immunogen constructs directed against dipeptide repeat proteins from c9orf72 | |
| KR20220040423A (ko) | 재조합 단백질을 포함하는 사스-코로나바이러스-2 감염증 예방 또는 치료용 백신 조성물 | |
| WO2007018198A1 (ja) | Hla-a2陽性者用hsp105由来癌拒絶抗原ペプチド及びこれを含む医薬 | |
| JP6756950B2 (ja) | ヒトヘルペスウイルス６ｂ抗原組成物 | |
| JP2004518410A5 (https=) | ||
| EP3650043A2 (en) | Compositions and treatments for haemophilus influenzae |